No. |
Variant name |
Chromosome position |
Chromatin state |
Related regulatory elements |
Target genes |
Extended variants |
Associated traits |
1 |
rs16987405 |
chr2:20346312-20346313 |
Weak transcription Enhancers Flanking Active TSS
|
n/a
|
n/a
|
LD-proxies of rSNPOverlapped rCNV
|
mRNA abundance
|
2 |
rs192235246 |
chr2:20346328-20346329 |
Weak transcription Enhancers Flanking Active TSS
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
3 |
rs184298253 |
chr2:20346356-20346357 |
Weak transcription Enhancers Flanking Active TSS
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
4 |
rs59070592 |
chr2:20346367-20346368 |
Weak transcription Enhancers Flanking Active TSS
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
5 |
rs145916451 |
chr2:20346386-20346387 |
Weak transcription Enhancers Flanking Active TSS
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
6 |
rs372041709 |
chr2:20346398-20346399 |
Weak transcription Enhancers Flanking Active TSS
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
7 |
rs535178439 |
chr2:20346415-20346416 |
Weak transcription Enhancers Flanking Active TSS
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
8 |
rs147826608 |
chr2:20346418-20346419 |
Weak transcription Enhancers Flanking Active TSS
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
9 |
rs188718801 |
chr2:20346420-20346421 |
Weak transcription Enhancers Flanking Active TSS
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
10 |
rs376853291 |
chr2:20346517-20346518 |
Weak transcription Enhancers Flanking Active TSS
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
11 |
rs141389435 |
chr2:20346538-20346539 |
Weak transcription Enhancers Flanking Active TSS
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
12 |
rs147023037 |
chr2:20346586-20346587 |
Weak transcription Enhancers Flanking Active TSS
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
13 |
rs554728779 |
chr2:20346609-20346610 |
Weak transcription Enhancers Flanking Active TSS
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
14 |
rs181371441 |
chr2:20346612-20346613 |
Weak transcription Enhancers Flanking Active TSS
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
15 |
rs576160138 |
chr2:20346635-20346636 |
Weak transcription Enhancers Flanking Active TSS
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
16 |
rs112695325 |
chr2:20346648-20346649 |
Weak transcription Enhancers Flanking Active TSS
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
17 |
rs981396 |
chr2:20346651-20346652 |
Weak transcription Enhancers Flanking Active TSS
|
n/a
|
n/a
|
LD-proxies of rSNPOverlapped rCNV
|
mRNA abundance
|
18 |
rs576459647 |
chr2:20346657-20346658 |
Weak transcription Enhancers Flanking Active TSS
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
19 |
rs542233767 |
chr2:20346658-20346659 |
Weak transcription Enhancers Flanking Active TSS
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
20 |
rs562242718 |
chr2:20346659-20346660 |
Weak transcription Enhancers Flanking Active TSS
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
21 |
rs533521953 |
chr2:20346673-20346674 |
Weak transcription Enhancers Flanking Active TSS
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
22 |
rs186183638 |
chr2:20346686-20346687 |
Weak transcription Enhancers Flanking Active TSS
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
23 |
rs564486105 |
chr2:20346718-20346719 |
Weak transcription Enhancers Flanking Active TSS
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
24 |
rs533453135 |
chr2:20346746-20346747 |
Weak transcription Enhancers Flanking Active TSS
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
25 |
rs137898627 |
chr2:20346753-20346754 |
Weak transcription Enhancers Flanking Active TSS
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
26 |
rs981395 |
chr2:20346774-20346775 |
Weak transcription Enhancers Flanking Active TSS
|
n/a
|
n/a
|
LD-proxies of rSNPOverlapped rCNV
|
n/a
|
27 |
rs116688349 |
chr2:20346781-20346782 |
Weak transcription Enhancers Flanking Active TSS
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
28 |
rs11898449 |
chr2:20346809-20346810 |
Weak transcription Enhancers
|
n/a
|
n/a
|
LD-proxies of rSNPOverlapped rCNV
|
n/a
|
29 |
rs569735158 |
chr2:20346823-20346824 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
30 |
rs375022136 |
chr2:20346849-20346850 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
31 |
rs535478946 |
chr2:20346865-20346866 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
32 |
rs149467208 |
chr2:20346962-20346963 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
33 |
rs551570048 |
chr2:20347013-20347014 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
34 |
rs571428040 |
chr2:20347014-20347015 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
35 |
rs537346838 |
chr2:20347034-20347035 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
36 |
rs541317544 |
chr2:20347054-20347055 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
37 |
rs34530162 |
chr2:20347069-20347070 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
38 |
rs35446805 |
chr2:20347076-20347077 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
39 |
rs560017236 |
chr2:20347078-20347079 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
40 |
rs11673898 |
chr2:20347090-20347091 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
41 |
rs148212196 |
chr2:20347111-20347112 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
42 |
rs555381930 |
chr2:20347116-20347117 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
43 |
rs566028160 |
chr2:20347215-20347216 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
44 |
rs189509846 |
chr2:20347224-20347225 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
45 |
rs79001905 |
chr2:20347240-20347241 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
46 |
rs141653356 |
chr2:20347262-20347263 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
47 |
rs146349847 |
chr2:20347269-20347270 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
48 |
rs564704286 |
chr2:20347356-20347357 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
49 |
rs4666367 |
chr2:20347379-20347380 |
Weak transcription Enhancers
|
n/a
|
n/a
|
LD-proxies of rSNPOverlapped rCNV
|
n/a
|
50 |
rs139696661 |
chr2:20347404-20347405 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|